Nasdaq
$125.83▲ 0.29%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.80BShares out 14.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
18- 1d agoAfter-hours26.10.24 05:054Ownership#●●●#●●●
PALVELLA THERAPEUTICS, INC.
Kathleen Goin, an insider at Palvella Therapeutics, Inc., reported a change in beneficial ownership of securities on October 21, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$125.83+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:21144Ownership
PALVELLA THERAPEUTICS, INC.
Kathleen Goin, an insider at Palvella Therapeutics, Inc., has filed an SEC Form 144 to report a proposed sale of company shares. This filing notifies the market of the insider's intent to dispose of shares, and investors should monitor the potential impact on stock performance.…more
$125.83+0.29%vs prev closeView filingShare - 10.14After-hours26.10.15 08:144Ownership
PALVELLA THERAPEUTICS, INC.
Director George M. Jenkins of Palvella Therapeutics (PVLA) filed a statement of changes in beneficial ownership of securities effective October 12, 2026. This filing serves as a standard disclosure regarding insider equity holdings.…more
$125.83+0.29%vs prev closeView filingShare
17 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 20:30#●●●#●●●
Palvella Therapeutics to Present Pediatric Clinical Data at PeDRA Conference…more
Palvella Therapeutics will present Phase 3 and Phase 2 clinical trial results for its investigational drug QTORIN, highlighting improvements in pediatric patients. As the therapy is still in the clinical stage without FDA approval, investors should monitor further regulatory progress.…more
$125.83+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Pre-market26.10.13 20:30
●●●●●●●● ●●●●● ●●●●●●
Palvella Therapeutics announced that its management team will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference. This event serves as a platform for corporate outreach and does not contain material information affecting the stock price.…more
$125.83+0.29%vs prev close - 10.12Pre-market26.10.12 20:33
●●●●●●●● ●●●●● ●●●●●●
Palvella's QTORIN rapamycin system demonstrated at least 40-fold lower systemic exposure compared to published oral sirolimus data in a Phase 3 substudy. This result suggests a potentially improved safety profile for the therapeutic candidate.…more
$125.83+0.29%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report